Thalidomide: an old sedative-hypnotic with anticancer activity?
Thalidomide is a synthetic derivative of glutamic acid with sedative-hypnotic activity, which caused devastating teratogenic effects in the 1960s. This paper reviews the possible mechanisms of its teratogenic effect, its new therapeutic indications, the proposed mechanisms for its antitumor activity and, finally, reviews published studies of its application in oncology. Current data demonstrates that thalidomide is clinically promising in multiple myeloma, glioblastoma multiforme and renal cell cancer. Furthermore, a beneficial effect of the drug has been proposed in cancer-related cachexia, which merits further investigation. Well-designed, randomized studies are warranted to establish the possible indications of thalidomide as an antitumor compound.
Gasparini
G
G
Division of Medical Oncology, Azienda Complesso Ospedaliero San Filippo Neri, Via Martinotti 20, 00135 Rome, Italy. gasparini.oncology@tiscalinet.it
Morabito
A
A
Magnani
E
E
Gattuso
D
D
Capaccetti
B
B
Alberti
A M
AM
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013723:Teratogens / Q000494:pharmacology* / Q000633:toxicity; D013792:Thalidomide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity
D000970:Antineoplastic Agents; D013723:Teratogens; D013792:Thalidomide